These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8191267)

  • 1. [Prevention of viral recurrence following liver transplantation for post-hepatitis B and B-delta cirrhosis].
    Mentha G; Giostra E; Perrin L; Widmann JJ; Stelling MJ; Easton J; Morel P; Huber O; Le Coultre C; Bühler L
    Schweiz Med Wochenschr; 1994 Apr; 124(15):637-41. PubMed ID: 8191267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recurrence of virus B hepatitis after liver transplantation].
    Gugenheim J; Crafa F; Fabiani P; Militerno G; Goubaux B; Saint-Paul MC; Ouzan D; Mouiel J
    Gastroenterol Clin Biol; 1992; 16(5):430-3. PubMed ID: 1326456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin.
    Terrault NA; Zhou S; Combs C; Hahn JA; Lake JR; Roberts JP; Ascher NL; Wright TL
    Hepatology; 1996 Dec; 24(6):1327-33. PubMed ID: 8938155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
    Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
    Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
    Samuel D; Zignego AL; Reynes M; Feray C; Arulnaden JL; David MF; Gigou M; Bismuth A; Mathieu D; Gentilini P
    Hepatology; 1995 Feb; 21(2):333-9. PubMed ID: 7843702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transplantation for viral hepatitis: the experience of the hepatobiliary center at Hospital Paul Brousse.
    Samuel D; Feray C; Bismuth H
    Clin Transpl; 1994; ():157-62. PubMed ID: 7547534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transplantation in European patients with the hepatitis B surface antigen.
    Samuel D; Muller R; Alexander G; Fassati L; Ducot B; Benhamou JP; Bismuth H
    N Engl J Med; 1993 Dec; 329(25):1842-7. PubMed ID: 8247035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation.
    Segovia R; Sánchez-Fueyo A; Rimola A; Grande L; Bruguera M; Costa J; Soguero C; Uriz J
    Liver Transpl; 2001 Feb; 7(2):106-12. PubMed ID: 11172393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation.
    Adler R; Safadi R; Caraco Y; Rowe M; Etzioni A; Ashur Y; Shouval D
    Hepatology; 1999 Apr; 29(4):1299-305. PubMed ID: 10094978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prevention of recurrent hepatitis B virus after liver transplantation.
    Ilan Y; Eid A; Tur-Kaspa R
    Isr J Med Sci; 1995 Aug; 31(8):469-73. PubMed ID: 7635695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.
    Caccamo L; Romeo R; Rossi G; Maggioni M; Radice F; Lunghi G; Colombo M; Fassati LR
    Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience.
    Roche B; Samuel D; Feray C; Majno P; Gigou M; Reynes M; Bismuth H
    Liver Transpl Surg; 1999 May; 5(3):166-74. PubMed ID: 10226106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis.
    Radecke K; Frühauf NR; Miller M; Ross B; Köditz R; Malagó M; Broelsch CE; Gerken G; Treichel U
    Liver Int; 2005 Feb; 25(1):101-8. PubMed ID: 15698406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of wild-type and precore mutant HBV infection after liver transplantation.
    Torre F; Wong PY; Macartney M; Williams R; Naoumov NV
    J Med Virol; 1999 Sep; 59(1):5-13. PubMed ID: 10440801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the changes of HBV serum markers and HBV DNA and the effects of perioperative factors after liver transplantation].
    Tang YM; Chen GH; He XS; Zhu XF; Chen MH
    Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):164-7. PubMed ID: 15760545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease.
    Arslan M; Wiesner RH; Sievers C; Egan K; Zein NN
    Liver Transpl; 2001 Apr; 7(4):314-20. PubMed ID: 11303291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.